Global Health Investment Corporation

GHIC layers philanthropic guarantees, typically from the Gates Foundation, into its fund structure to absorb potential losses on specific investments. This credit enhancement reduces risk for private limited partners, making commercial returns feasible even when backing products for low-income-country markets. The mechanism allows GHIC to pursue deals that conventional venture capital would deem unbankable.

Managing Partners Peter Zuromskis, a former healthcare investment banker at JPMorgan, and David Glynn, a former GlaxoSmithKline vaccines executive, jointly lead the firm. They are supported by an investment team with backgrounds in pharmaceuticals, global health policy, and development finance. Investment committee composition is not publicly detailed.

GHIC focuses on late-stage development, typically products that have already cleared early clinical trials and require financing for registration, manufacturing scale-up, or distribution. The firm writes equity and structured debt checks in the $5 million to $15 million range, occasionally participating in smaller follow-on rounds.

GHIC primarily executes direct equity and debt investments in product developers. The firm is not known to operate as a fund-of-funds, and its public disclosures focus on direct portfolio companies advancing specific medical technologies.

The Bill & Melinda Gates Foundation was an anchor investor in GHIC's initial fund and provides a partial guarantee facility that underwrites certain portfolio risks. The foundation does not control investment decisions, but its presence constrains the firm to a public-health mandate targeting diseases that disproportionately affect low-income populations.

GHIC does not invest in non-healthcare sectors. Within life sciences, it explicitly avoids early-stage discovery assets and pure-play commercial biotech aimed solely at high-income markets. The firm's mandate is restricted to technologies addressing infectious diseases, maternal and child health, and other conditions with significant disease burdens in low-resource settings.

GHIC is a for-profit corporation, not a foundation. Its philanthropic relationships function through contractual guarantee agreements rather than grant-making vehicles. Returns flow to private LPs, but portfolio eligibility is determined by a mission screen that ensures investee products serve underserved populations.